Date of Award
Master of Physician Assistant Studies
Physician Assistant Education
Patients with chronic obstructive pulmonary disease (COPD) have high rates of cardiovascular comorbidities, including hypertension, ischemic heart disease, and heart failure. These comorbidities further complicate management of COPD patients. Cardiovascular complications are especially difficult to manage during acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Multiple factors are contributory, including hypoxemia, tachycardia, increased inflammation, and arterial stiffness. Cardioselective beta-blockers have been proven to be safe and effective in managing cardiovascular conditions such as heart failure and arrhythmias and are recommended for acutely decompensated heart failure and myocardial infarction in the setting of AECOPD. Benefits include reducing all-cause mortality and the risk of COPD exacerbations.1 However, beta-blockers continue to be underused in COPD patients due to lingering concerns about bronchospasm leading to exacerbation of COPD symptoms requiring hospitalization. Whether the use of beta-blockers for cardiovascular disease in patients with COPD would decrease pulmonary function or increase frequency of exacerbations, hospitalizations, and mortality will be examined.
Kang, Veshudha, "Beta-blockers for the treatment of cardiovascular disease in COPD patients" (2020). Physician's Assistant Program Capstones. 63.